BMJ Global Health · 2024 · 44 citations · 44 references
PharmacyHealth SciencesPharmacoeconomicsCost-effectiveness AnalysisHealth EconomicsHealth Technology AssessmentContingent ValuationCost-effectiveness ThresholdsEconomic EvaluationUtility Elicitation MethodsWillingness To PayWillingness-to-pay ThresholdsCost-effectivenessHealth Technology Assessment ModelingInterval RegressionQuality-adjusted Life Year PerspectiveQuality-adjusted Life Year ValuationRare Diseases ThresholdsSocietal Willingness-to-payThresholds
INTRODUCTION: The willingness to pay per quality-adjusted life year gained (WTP/Q) is commonly used to determine whether an intervention is cost-effective in health technology assessment. This study aimed to evaluate the WTP/Q for different disease scenarios in a Chinese population. METHODS: The study employed a quadruple-bounded dichotomous choice contingent valuation method to estimate the WTP/Q in the general public. The estimation was conducted across chronic, terminal and rare disease scenarios. Face-to-face interviews were conducted in a Chinese general population recruited from Jiangsu province using a convenience sampling method. Interval regression analysis was performed to determine the relationship between respondents' demographic and socioeconomic conditions and WTP/Q. Sensitivity analyses of removing protest responses and open question analyses were conducted. RESULTS: A total of 896 individuals participated in the study. The WTP/Q thresholds were 128 000 Chinese renminbi (RMB) ($36 364) for chronic diseases, 149 500 RMB ($42 472) for rare diseases and 140 800 RMB ($40 000) for terminal diseases, equivalent to 1.76, 2.06 and 1.94 times the gross domestic product per capita in China, respectively. The starting bid value had a positive influence on participants' WTP/Q. Additionally, residing in an urban area (p<0.01), and higher household expenditure (p<0.01), educational attainment (p<0.02) and quality of life (p<0.02) were significantly associated with higher WTP/Q. Sensitivity analyses demonstrated the robustness of the results. CONCLUSION: This study implies that tailored or varied rather than a single cost-effectiveness threshold could better reflect community preferences for the value of a healthy year. Our estimates hold significance in informing reimbursement decision-making in health technology assessment in China.
44
Ted O’Donoghue, Matthew Rabin · American Economic Review · 1999 · 3.2K citations
Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research
Beth Woods, Paul Revill, Mark Sculpher et al. · Value in Health · 2016 · 925 citations · Full text
Cost–effectiveness thresholds: pros and cons
Melanie Bertram, Jeremy A. Lauer, Kees de Joncheere et al. · Bulletin of the World Health Organization · 2016 · 788 citations · Full text
Pharmacy, Economics, Health Policy +17
Estimating an EQ-5D-5L Value Set for China
Nan Luo, Gordon Liu, LI Ming-hui et al. · Value in Health · 2017 · 725 citations · Full text